Summary of Study ST002063
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001306. The data can be accessed directly via it's Project DOI: 10.21228/M8WT4R This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Study ID | ST002063 |
| Study Title | Intravenous lipopolysaccharide infusion and the bovine metabolome |
| Study Type | MS plasma lipidomics and metabolomics |
| Study Summary | The effects of lipopolysaccharides (i.e., endotoxin; LPS) on metabolism are poorly defined in lactating dairy cattle experiencing hyperlipidemia. Our objective was to explore the effects of acute intravenous LPS administration on metabolism in late-lactation Holstein cows experiencing hyperlipidemia. Ten non-pregnant lactating Holstein cows (273 ± 35 d in milk) were administered a single bolus of saline (3 mL of saline; n = 5) or LPS (0.375 μg of LPS/kg of body weight; n = 5). Simultaneously, cows were intravenously infused a triglyceride emulsion and fasted for 16 h to induce hyperlipidemia in an attempt to model the periparturient period. Blood was sampled at routine intervals. Changes in circulating total fatty acid concentrations and inflammatory parameters were measured. Plasma samples were analyzed using untargeted lipidomics and metabolomics. Endotoxin increased circulating serum amyloid A, LPS-binding protein, and cortisol concentrations. Endotoxin administration decreased plasma lysophosphatidylcholine (LPC) concentrations and increased select plasma ceramide concentrations. These outcomes suggest modulation of the immune response and insulin action. Lipopolysaccharide decreased the ratio of phosphatidylcholine to phosphatidylethanomanine, which potentially indicate a decrease in the hepatic activation of phosphatidylethanolamine N-methyltransferase and triglyceride export. Endotoxin administration also increased plasma concentrations of pyruvic and lactic acids, and decreased plasma citric acid concentrations, which implicate the upregulation of glycolysis and downregulation of the citric acid cycle (i.e., the Warburg effect), potentially in leukocytes. Acute intravenous LPS administration decreased circulating LPC concentrations, modified ceramide and glycerophospholipid concentrations, and influenced intermediary metabolism in dairy cows experiencing hyperlipidemia. |
| Institute | Cornell University |
| Department | Animal Science |
| Laboratory | McFadden lab |
| Last Name | Javaid |
| First Name | Awais |
| Address | 400 Warren Rd, Ithaca, New York, 14850, USA |
| aj366@cornell.edu | |
| Phone | 6072287246 |
| Submit Date | 2022-01-09 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | mzXML |
| Analysis Type Detail | LC-MS |
| Release Date | 2022-06-30 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Factors:
Subject type: Mammal; Subject species: Bos taurus (Factor headings shown in green)
| mb_sample_id | local_sample_id | Time |
|---|---|---|
| SA194101 | 233-10336_CON-IL_12.raw | 12 | Treatment:CON | Category:Lipidomics |
| SA194102 | 234-9855_CON-IL_12.raw | 12 | Treatment:CON | Category:Lipidomics |
| SA194103 | 231-9852_CON-IL_12.raw | 12 | Treatment:CON | Category:Lipidomics |
| SA194104 | 230-9609_CON-IL_12.raw | 12 | Treatment:CON | Category:Lipidomics |
| SA194105 | 232-9610_CON-IL_12.raw | 12 | Treatment:CON | Category:Lipidomics |
| SA194106 | 238-9785_LPS-IL_12.raw | 12 | Treatment:LPS | Category:Lipidomics |
| SA194107 | 237-10008_LPS-IL_12.raw | 12 | Treatment:LPS | Category:Lipidomics |
| SA194108 | 235-10218_LPS-IL_12.raw | 12 | Treatment:LPS | Category:Lipidomics |
| SA194109 | 239-10103_LPS-IL_12.raw | 12 | Treatment:LPS | Category:Lipidomics |
| SA194110 | 236-8473_LPS-IL_12.raw | 12 | Treatment:LPS | Category:Lipidomics |
| SA194111 | 241-9852_CON-IL_16.raw | 16 | Treatment:CON | Category:Lipidomics |
| SA194112 | 240-9609_CON-IL_16.raw | 16 | Treatment:CON | Category:Lipidomics |
| SA194113 | 244-9855_CON-IL_16.raw | 16 | Treatment:CON | Category:Lipidomics |
| SA194114 | 242-9610_CON-IL_16.raw | 16 | Treatment:CON | Category:Lipidomics |
| SA194115 | 243-10336_CON-IL_16.raw | 16 | Treatment:CON | Category:Lipidomics |
| SA194116 | 9609CON-IL-16_NEG.raw | 16 | Treatment:CON | Category:Metabolomics |
| SA194117 | 9852CON-IL-16_NEG.raw | 16 | Treatment:CON | Category:Metabolomics |
| SA194118 | 9855CON-IL-16_NEG.raw | 16 | Treatment:CON | Category:Metabolomics |
| SA194119 | 10336CON-IL-16_NEG.raw | 16 | Treatment:CON | Category:Metabolomics |
| SA194120 | 9610CON-IL-16_NEG.raw | 16 | Treatment:CON | Category:Metabolomics |
| SA194121 | 249-10103_LPS-IL_16.raw | 16 | Treatment:LPS | Category:Lipidomics |
| SA194122 | 245-10218_LPS-IL_16.raw | 16 | Treatment:LPS | Category:Lipidomics |
| SA194123 | 246-8473_LPS-IL_16.raw | 16 | Treatment:LPS | Category:Lipidomics |
| SA194124 | 248-9785_LPS-IL_16.raw | 16 | Treatment:LPS | Category:Lipidomics |
| SA194125 | 247-10008_LPS-IL_16.raw | 16 | Treatment:LPS | Category:Lipidomics |
| SA194126 | 10218LPS-IL-16_NEG.raw | 16 | Treatment:LPS | Category:Metabolomics |
| SA194127 | 10103LPS-IL-16_NEG.raw | 16 | Treatment:LPS | Category:Metabolomics |
| SA194128 | 8473LPS-IL-16_NEG.raw | 16 | Treatment:LPS | Category:Metabolomics |
| SA194129 | 9785LPS-IL-16_NEG.raw | 16 | Treatment:LPS | Category:Metabolomics |
| SA194130 | 10008LPS-IL-16_NEG.raw | 16 | Treatment:LPS | Category:Metabolomics |
| SA194131 | 251-9852_CON-IL_24.raw | 24 | Treatment:CON | Category:Lipidomics |
| SA194132 | 254-9855_CON-IL_24.raw | 24 | Treatment:CON | Category:Lipidomics |
| SA194133 | 250-9609_CON-IL_24.raw | 24 | Treatment:CON | Category:Lipidomics |
| SA194134 | 253-10336_CON-IL_24.raw | 24 | Treatment:CON | Category:Lipidomics |
| SA194135 | 252-9610_CON-IL_24.raw | 24 | Treatment:CON | Category:Lipidomics |
| SA194136 | 257-10008_LPS-IL_24.raw | 24 | Treatment:LPS | Category:Lipidomics |
| SA194137 | 259-10103_LPS-IL_24.raw | 24 | Treatment:LPS | Category:Lipidomics |
| SA194138 | 255-10218_LPS-IL_24.raw | 24 | Treatment:LPS | Category:Lipidomics |
| SA194139 | 258-9785_LPS-IL_24.raw | 24 | Treatment:LPS | Category:Lipidomics |
| SA194140 | 256-8473_LPS-IL_24.raw | 24 | Treatment:LPS | Category:Lipidomics |
| SA194141 | 264-9855_CON-IL_48.raw | 48 | Treatment:CON | Category:Lipidomics |
| SA194142 | 260-9609_CON-IL_48.raw | 48 | Treatment:CON | Category:Lipidomics |
| SA194143 | 262-9610_CON-IL_48.raw | 48 | Treatment:CON | Category:Lipidomics |
| SA194144 | 261-9852_CON-IL_48.raw | 48 | Treatment:CON | Category:Lipidomics |
| SA194145 | 263-10336_CON-IL_48.raw | 48 | Treatment:CON | Category:Lipidomics |
| SA194146 | 265-10218_LPS-IL_48.raw | 48 | Treatment:LPS | Category:Lipidomics |
| SA194147 | 266-8473_LPS-IL_48.raw | 48 | Treatment:LPS | Category:Lipidomics |
| SA194148 | 267-10008_LPS-IL_48.raw | 48 | Treatment:LPS | Category:Lipidomics |
| SA194149 | 269-10103_LPS-IL_48.raw | 48 | Treatment:LPS | Category:Lipidomics |
| SA194150 | 268-9785_LPS-IL_48.raw | 48 | Treatment:LPS | Category:Lipidomics |
| SA194151 | 211-9852_CON-IL_4.raw | 4 | Treatment:CON | Category:Lipidomics |
| SA194152 | 210-9609_CON-IL_4.raw | 4 | Treatment:CON | Category:Lipidomics |
| SA194153 | 214-9855_CON-IL_4.raw | 4 | Treatment:CON | Category:Lipidomics |
| SA194154 | 213-10336_CON-IL_4.raw | 4 | Treatment:CON | Category:Lipidomics |
| SA194155 | 212-9610_CON-IL_4.raw | 4 | Treatment:CON | Category:Lipidomics |
| SA194156 | 216-8473_LPS-IL_4.raw | 4 | Treatment:LPS | Category:Lipidomics |
| SA194157 | 218-9785_LPS-IL_4.raw | 4 | Treatment:LPS | Category:Lipidomics |
| SA194158 | 217-10008_LPS-IL_4.raw | 4 | Treatment:LPS | Category:Lipidomics |
| SA194159 | 215-10218_LPS-IL_4.raw | 4 | Treatment:LPS | Category:Lipidomics |
| SA194160 | 219-10103_LPS-IL_4.raw | 4 | Treatment:LPS | Category:Lipidomics |
| SA194161 | 222-9610_CON-IL_8.raw | 8 | Treatment:CON | Category:Lipidomics |
| SA194162 | 220-9609_CON-IL_8.raw | 8 | Treatment:CON | Category:Lipidomics |
| SA194163 | 224-9855_CON-IL_8.raw | 8 | Treatment:CON | Category:Lipidomics |
| SA194164 | 223-10336_CON-IL_8.raw | 8 | Treatment:CON | Category:Lipidomics |
| SA194165 | 221-9852_CON-IL_8.raw | 8 | Treatment:CON | Category:Lipidomics |
| SA194166 | 9855CON-IL-8_NEG.raw | 8 | Treatment:CON | Category:Metabolomics |
| SA194167 | 10336CON-IL-8_NEG.raw | 8 | Treatment:CON | Category:Metabolomics |
| SA194168 | 9852CON-IL-8_NEG.raw | 8 | Treatment:CON | Category:Metabolomics |
| SA194169 | 9609CON-IL-8_NEG.raw | 8 | Treatment:CON | Category:Metabolomics |
| SA194170 | 9610CON-IL-8_NEG.raw | 8 | Treatment:CON | Category:Metabolomics |
| SA194171 | 227-10008_LPS-IL_8.raw | 8 | Treatment:LPS | Category:Lipidomics |
| SA194172 | 229-10103_LPS-IL_8.raw | 8 | Treatment:LPS | Category:Lipidomics |
| SA194173 | 228-9785_LPS-IL_8.raw | 8 | Treatment:LPS | Category:Lipidomics |
| SA194174 | 226-8473_LPS-IL_8.raw | 8 | Treatment:LPS | Category:Lipidomics |
| SA194175 | 225-10218_LPS-IL_8.raw | 8 | Treatment:LPS | Category:Lipidomics |
| SA194176 | 8473LPS-IL-8_NEG.raw | 8 | Treatment:LPS | Category:Metabolomics |
| SA194177 | 9785LPS-IL-8_NEG.raw | 8 | Treatment:LPS | Category:Metabolomics |
| SA194178 | 10103LPS-IL-8_NEG.raw | 8 | Treatment:LPS | Category:Metabolomics |
| SA194179 | 10008LPS-IL-8_NEG.raw | 8 | Treatment:LPS | Category:Metabolomics |
| SA194180 | 10218LPS-IL-8_NEG.raw | 8 | Treatment:LPS | Category:Metabolomics |
| SA194098 | QC_3_NEG.raw | . | Treatment:. | Category:Metabolomics |
| SA194099 | QC_1_NEG.raw | . | Treatment:. | Category:Metabolomics |
| SA194100 | QC_2_NEG.raw | . | Treatment:. | Category:Metabolomics |
| SA194078 | 202-9610_CON-IL_0.raw | - | Treatment:CON | Category:Lipidomics |
| SA194079 | 204-9855_CON-IL_0.raw | - | Treatment:CON | Category:Lipidomics |
| SA194080 | 200-9609_CON-IL_0.raw | - | Treatment:CON | Category:Lipidomics |
| SA194081 | 201-9852_CON-IL_0.raw | - | Treatment:CON | Category:Lipidomics |
| SA194082 | 203-10336_CON-IL_0.raw | - | Treatment:CON | Category:Lipidomics |
| SA194083 | 10336CON-IL-0_NEG.raw | - | Treatment:CON | Category:Metabolomics |
| SA194084 | 9610CON-IL-0_NEG.raw | - | Treatment:CON | Category:Metabolomics |
| SA194085 | 9852CON-IL-0_NEG.raw | - | Treatment:CON | Category:Metabolomics |
| SA194086 | 9855CON-IL-0_NEG.raw | - | Treatment:CON | Category:Metabolomics |
| SA194087 | 9609CON-IL-0_NEG.raw | - | Treatment:CON | Category:Metabolomics |
| SA194088 | 206-8473_LPS-IL_0.raw | - | Treatment:LPS | Category:Lipidomics |
| SA194089 | 209-10103_LPS-IL_0.raw | - | Treatment:LPS | Category:Lipidomics |
| SA194090 | 208-9785_LPS-IL_0.raw | - | Treatment:LPS | Category:Lipidomics |
| SA194091 | 205-10218_LPS-IL_0.raw | - | Treatment:LPS | Category:Lipidomics |
| SA194092 | 207-10008_LPS-IL_0.raw | - | Treatment:LPS | Category:Lipidomics |
| SA194093 | 10008LPS-IL-0_NEG.raw | - | Treatment:LPS | Category:Metabolomics |
| SA194094 | 8473LPS-IL-0_NEG.raw | - | Treatment:LPS | Category:Metabolomics |
